About this item:

257 Views | 184 Downloads

Author Notes:

Address correspondence to: Chia-shi Wang, Division of Pediatric Nephrology, 2015 Uppergate Drive NE, Atlanta, GA, 30322-1015, chia-shi.wang@emory.edu, phone 404-727-5728, fax 404-727-8997

The content is solely the responsibility of the authors and does not necessary represent the official views of the National Institutes of Health.

Compliance with Ethical Standards: Ethical approval. The study was approved by the Children's Healthcare of Atlanta Institutional Review Board. For this type of study, formal consent is not required.

Disclosure. The authors declare that they have no potential conflicts of interest to disclose.

Subjects:

Research Funding:

Chia-shi Wang is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Pediatrics
  • Urology & Nephrology
  • Ofatumumab
  • Nephrotic syndrome
  • Focal segmental
  • Glomerulosclerosis
  • Children
  • CLINICAL-FEATURES
  • CONTROLLED-TRIAL
  • RITUXIMAB
  • CHILDREN
  • MULTICENTER
  • GUIDELINES
  • MANAGEMENT
  • KDIGO

Ofatumumab for the treatment of childhood nephrotic syndrome

Tools:

Journal Title:

Pediatric Nephrology

Volume:

Volume 32, Number 5

Publisher:

, Pages 835-841

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background: Ofatumumab is a humanized anti-CD20 monoclonal antibody that has recently garnered interest as a potential therapeutic agent for nephrotic syndrome. We report our center’s experience in administering ofatumumab to five pediatric patients with idiopathic nephrotic syndrome. Methods: Between March 2015 and November 2016, five patients were treated with ofatu mumab. One patient had post-transplant recurrent focal segmental glomerulosclerosis (FSGS) which had been resistant to plasmapheresis and numerous immunosuppressive agents. Four patients had nephrotic syndrome in their native kidneys, one with initial steroid-resistant disease and the others with subsequent development of steroid resistance. Two of the patients were treated with a desensitization protocol after experiencing hypersensitivity reactions to ofatumumab. Results: One patient did not complete ofatumumab treatment due to infusion reactions. Of the four remaining patients, three achieved complete remission after treatment, and one achieved partial remission. One of the patients achieving complete remission represents the first reported case of successful treatment of post-transplant recurrent FSGS using ofatumumab. Two patients who received ofatumumab with our desensitization protocol were able to complete their treatments after initially experiencing hypersensitivity reactions. Conclusions: Ofatumumab may be an effective treatment for refractory childhood nephrotic syndrome and post-transplant recurrent FSGS. A desensitization protocol may be helpful to address hypersensitivity reactions.

Copyright information:

© 2017, IPNA.

Export to EndNote